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OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
extracorporeal shock wave therapy is effective in treating shoulder tendonitis. 
 
STUDY DESIGN: This review paper analyzes two, double-blind, randomized control trials 
(RCTs) and one retrospective cohort study. The population included adults with calcified or non-
calcified shoulder tendinitis. The intervention was extracorporeal shock wave therapy (ESWT). 
The groups receiving ESWT in the RCTs were compared to those receiving placebo probes. 
 
DATA SOURCE: Each article was a primary research design published in English after 2015 in 
peer-review journals. 
 
OUTCOMES: The outcomes measured were patient-oriented evidence that matters, including 
pain and disability. The outcomes were measured by questionnaires and surveys including NRS, 
CMS, SPADI, and VAS. The summary of statistics was reported using mean change from 
baseline, 95% confidence intervals, standard deviations, and p-values. 
 
RESULTS: Lie et al. RCT studied those with non-calcified CRTC tendonitis. There was a 
statistically significant decrease in mean NRS and CMS score in the group receiving ESWT 
compared to the control group receiving the placebo probe (p < 0.001; Medicine. 2017;96(35):1-
4. doi:10.1097/MD.0000000000007940). Kvalaag et al. RCT studied those with non-calcified 
and calcified RTC tendonitis. There was no statistically significant difference in the group 
receiving ESWT with supervised exercises compared to the group receiving sham ESWT with 
supervised exercises (p = .76); however, both groups had a decrease in mean SPADI score (Am J 
Sports Med. 2017;45(11):2547-2554. doi: 10.1177/0363546517707505 [doi]). Malliaropoulos et 
al. retrospective cohort study showed a statistically significant improvement in shoulder pain, 
remission rate, and recurrence rate in those with calcified shoulder tendinopathy (Musculoskelet 
Disord. 2017;18(1):x. doi: 10.1186/s12891-017-1873-x [doi]). 
 
CONCLUSION: It is inconclusive as to whether or not ESWT is effective in treating shoulder 
tendonitis. Two studies showed statistically significant improvements in shoulder pain and 
function after ESWT, while one study did not. Further studies are needed to determine which 
specific type of shoulder tendonitis would benefit most from ESWT.  
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INTRODUCTION 
 
Shoulder tendonitis is an acute, subacute, or chronic inflammatory condition that is 
largely due to trauma and overuse of the rotator cuff tendons. Shoulder tendonitis is a common 
condition that medical professionals may encounter in primary care or orthopedic/sports 
medicine settings. Extracorporeal shock wave therapy (ESWT) is an emerging treatment for 
many common musculoskeletal complaints, including plantar fasciitis, epicondylitis and rotator 
cuff tendonitis.1 Medical professionals need to be educated on ESWT in order to determine good 
candidates for the procedure.  
Shoulder tendinopathy is the third most common orthopedic complaint in the United 
States, and it accounts for 4.5 billion healthcare visits.4 The prevalence of shoulder tendonitis 
increases with age but can be seen in a younger population as well, commonly in athletes. Many 
shoulder complaints are due to rotator cuff (RTC) etiologies. The RTC includes four main 
tendons: supraspinatus, infraspinatus, subscapularis and teres minor. When there is damage to 
these tendons the body elicits an inflammatory response. As inflammation ensues during the 
acute phase, lasting anywhere from 3 weeks to 6 months5, patients will complain of pain and 
decreased mobility.  
This condition can be self-limiting, but other times scar tissue and calcifications can form 
causing chronic RTC (CRTC) tendonitis. In calcified RTC tendonitis, calcium hydroxyapatite 
crystals form along the tendons, most commonly the supraspinatus tendon, and it can impede 
mobility and blood flow to the muscles creating muscle hypoxia.5 Patients may also have 
decreased range of motion (specifically with abduction), crepitus, impingement sign, and point 
tenderness.5 
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Typically, conservative measures are first employed to treat shoulder tendonitis. These 
include NSAIDs, physical therapy, corticosteroid injections, and transcutaneous nerve 
stimulation.1,5 When these measures fail, arthroscopic surgery can be performed. 
ESWT is proposed as a treatment for shoulder tendonitis because it is a non-invasive, 
cost-effective procedure that has minimal complications and minimal recovery time. In 2015, it 
was reported in the International Journal of Surgery that patients saved $2,000 when they 
choose ESWT compared to surgery.2 In Europe, surgery cost 5-7x higher than ESWT and were 
associated with a longer time off work2. The cost of ESWT was €2700-€4300, which estimates 
to US$2,974-$4,736.2,3 Additionally, ESWT is effective because it breaks down fibrous tissue, 
restores blood flow, stimulates formation of collagen, and improves sensation of pain.1,5 
OBJECTIVE  
 
The objective of this selective EBM review is to determine whether or not extracorporeal 
shock wave therapy is effective in treating shoulder tendonitis. 
METHODS  
 
In searching for data sources, the keywords that were used were extracorporeal shock 
wave therapy, shoulder tendonitis, tendinopathy, and shoulder pain. Articles were researched 
through PubMed and Alt Health Watch. Articles were chosen that aimed to answer the question 
in the objective and that had outcomes that were patient oriented evidence that matters (POEMs). 
The search’s inclusion criteria were primary research design and studies published after 2015. 
The search’s exclusion criteria were studies published before 2015. The summary of statistics 
was reported as mean change from baseline, 95% confidence intervals (CIs), standard deviations 
(SDs) and p-values. 
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The three studies selected included two randomized, double-blind, placebo-controlled 
trials; and one uncontrolled, retrospective, single-center cohort analysis. Each article was 
published in English. They were published in peer-review journals in 2017, including The 
BioMed Central Journal of Musculoskeletal Disorders, Medicine, and The American Journal of 
Sports Medicine. 
In this review paper, the population studied was adults with calcified or non-calcified 
shoulder tendinitis. The intervention studied was extracorporeal shock wave therapy. The 




The outcomes measured were shoulder pain and disability. This was achieved through 
self-reported surveys and questionnaires including: Numeric Rating Scale (NRS), Constant 
Murley Score (CMS), Shoulder Pain and Disability Index (SPADI) and Visual Analog Score 
(VAS). 
The SPADI measured shoulder pain and function. It consists of 13 questions, 5 of which 
assess pain and 8 that assess disability. Each question is scored using a visual analog scale of 0-
11. The total SPADI score ranges from 0-100, with a higher score indicating higher pain and 
disability.1 The VAS assessed pain on a scale of 0-10 with associated pictures depicting the 
levels of pain.5 The NRS also assessed pain on a scale of 0-10, with 10 being the worst possible 
pain6. The CMS measured shoulder functionality on a 0-100 scale, with a higher score indicating 
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Table 1. Demographics and characteristics of included studies 








Li et al. 
(2017)6 
 
RCT 84 18-65 Dx of CRTC 
tendonitis w/o 
calcification, h/o 
clinical signs of 
chronic tendonitis 
for > 6 mo, no 
alternative therapy 
(including ESWT) 








ds, skin ds, severe 
mental ds 
15 ESWT: 3,000 
pulses of 0.11 
mJ/mm2 at 
15Hz x 5 
sessions with 





RCT 143 25-70 Sx of subacromial 
shoulder pain w/ 
and w/o 
calcifications for > 
3 mo 
Pain with either 
abduction of arm 
in 45 degrees 
and/or external 






H/o previous surgery 
or ESWT, 
corticosteroid 
injection in last 6 
wks, SPADI score 
<20, instability of 
shoulder, RA, full 







8 ESWT: 2,000 
pulses of 0.14-
0.33 mJ/mm2 




once/wk x 4 
wks (in combo 
with ESWT), 
then twice/wk 









67 26-63 Dx of calcified 
shoulder 
tendinopathy, pain 









H/o surgery, ESWT, 
corticosteroid 
injection in past 6 
wks, or malignancy 
0 ESWT: Mean 
of 2,175 
pulses of 1.7 
mJ/mm2 at 
5Hz for a 
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RESULTS 
 
A randomized, double-blinded control trial, conducted by Li et al., studied the efficacy of 
ESWT in 84 patients with non-calcified CRTC tendonitis, compared to a placebo probe. 
Participants were randomly assigned to the intervention group or control group. The intervention 
group received ESWT at 3,000 pulses of 0.11 mJ/mm2 at 15Hz for 5 sessions with 3-day 
intervals in between.6 The control group received the placebo probe for 5 sessions with 3-day 
intervals in between.6 In this study, three participants withdrew for consent withdrawal, and 
twelve were lost to follow-up. There were 35 participants that completed treatment in the 
interventional group and 34 participants that completed treatment in the control group. All 
patients were analyzed with intention-to-treat (ITT). The outcomes, pain and disability, were 
measured by the NRS and CMS and evaluated using mean change from baseline after 8 weeks of 
treatment, a 95% confidence interval and a p-value that was statistically significant when p < 
0.05 (Table 2). After 8 weeks of the study, there was a 4.5 decrease in NRS score and a 27.2 
increase in CMS score.6 The 95% CIs had a narrow range, and the results were statistically 
significant when compared to the control group, with a p-value < 0.01 (Table 2).6  
Table 2. Outcome measurements after 8 weeks of treatment in Lie et al. study6  
Outcomes Mean Change from Baseline (95% CI) P value 
 ESWT Placebo  
NRS -4.5 (-7.2, -2.3) -0.5 (-0.9, 0.6) **< .01 
CMS 27.2 (18.6, 38.3) 14.1 (8.8, 20.2) **< .01 
  **statistically significant difference (p = <0.05) 
 
Another randomized, double-blinded, control trial, conducted by Kvalvaag et al., studied 
the effectiveness of ESWT in combination with an appropriate exercise regimen to treat calcified 
and non-calcified RTC tendinopathy, compared to those receiving the sham ESWT. The study 
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included 143 participants that were randomly assigned to the interventional group or the control 
group. The interventional group received ESWT at 2,000 pulses of 0.14-0.33 mJ/mm2 once a 
week for 4 weeks on painful shoulder tendons that were determined with isometric testing.1 
Additionally, they underwent supervised exercises once a week for 4 weeks (with ESWT) and 
then twice a week for 4 weeks (with no ESWT). The control group received the same exercise 
regimen and a sham ESWT, which was identical in appearance but delivered no extracorporeal 
shock waves. In this study, three participants were lost to follow-up, and five participants 
discontinued intervention due to pain after sham ESWT, sudden onset of other disorder, 
development of adhesive capsulitis or synovial chondromatosis. There were 65 participants that 
completed treatment in the interventional group and 70 participants that completed treatment in 
the control group. All patients were analyzed with ITT. 
The outcomes, pain and disability, were measured using the SPADI self-reported 
questionnaire and evaluated using mean change from baseline after 24 weeks of treatment, 95% 
CIs, and a p-value that was statistically significant if p < 0.05 (Table 3).1 After 24 weeks of the 
study, there was a 23.6-point decrease in SPADI score for those receiving ESWT and a 24.4-
point decrease in SPADI score in those receiving the sham ESWT1. The treatment affect was 
small with a wide-ranged CI and high SDs (Table 3). The p-value = 0.76, which was not 
statistically significant (Table 3).1  






Mean Change from 
Baseline 
Mean Treatment 
Effect (95% CI) 
P value 
 ESWT Sham ESWT Sham   
SPADI 51.9 (16.7) 51.8 (17.5) -23.6 -24.4 0.7 (-6.9 to 8.3) .76 
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A retrospective cohort analysis, conducted by Malliaropoulos et al., evaluated ESWT in 
patients with calcified shoulder tendinopathy. In this study, there were 67 patients that were 
evaluated who were diagnosed with calcified shoulder tendinopathy with pain that lasted for at 
least three months. Three patients discontinued their treatment due to financial reasons or time 
constraints. There were 64 patients that completed their treatment protocol, 39% men and 61% 
women.5 The average duration of shoulder pain experienced by this group of patients prior to 
treatment was 12.5 months,, and the patients completed an average number of 7 ESWT sessions.5  
In this study, Malliaropoulos et al., each patient had an individualized treatment protocol 
determined by their severity of pain, tolerance of ESWT, and response to treatment. The 
outcome of pain was measured by the self-reported VAS score, which was taken at baseline, 
immediately post-treatment, 1-month post treatment, 3-months post-treatment and 1-year post 
treatment. Successful treatment was defined as those that had a 60% decrease in their VAS score. 
VAS scores were evaluated by using mean change from baseline, standard deviations (SDs), and 
a p-value that was statistically significant if <0.001 (Table 4).5 There was a 3.4 mean decrease in 
VAS score from baseline immediately post treatment (52% decrease), 4.1 decrease 2-months 
post treatment (62% decrease), 5.0 decrease 3-months post treatment (75% decrease), and 5.8 
decrease 1-year post treatment (88% decrease). The SDs ranged from 0.8-1.1. The results were 
statistically significant with a p value = 0.000 (Table 4).5 
DISCUSSION 
ESWT is an affordable, non-invasive, emerging therapy for those with shoulder tendonitis. In 
the Li et al. RCT study, ESWT was found to be clinically important for patients with non-
calcified CRTC tendonitis. There was a statistically significantly improvement in the participants 
pain and shoulder function after receiving ESWT for four weeks, compared to those receiving no 
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ESWT. Additionally, there were no adverse events reported.6 A limitation in this study was that 
the sample size was small and was only conducted at a single center with patients of Chinse Han 
ethnicity.6 
Table 4. Outcome measurements at various follow-ups in Malliaropoulos et al. study5 













3.2 0.8 3.4 52% **0.000 
1-month  2.6 0.9 4.1 62% **0.000 
3-month 1.7 1.0 5.0 75% **0.000 
1-year 0.8 1.0 5.8 88% **0.000 
**statistically significant difference (p = <0.001) 
 
In the Kvalaag et al. study, there was no statistically significant improvement in pain for 
those who received ESWT and supervised exercises, compared to those that received sham 
ESWT and supervised exercises. Both the control group and the interventional group reported 
improvements in pain, but there was no statistically significant difference between both groups. 
A limitation to this study is that while patients met the common clinical criteria, they had 
different findings on their ultrasound.1 Furthermore, the physical therapists who were solely in 
charge of administering the ESWT or sham ESWT were not blinded.1 
In the Malliaropoulos et al. study, patients receiving an individualized protocol for ESWT to 
treat calcified shoulder tendonitis saw statistically significant reduction in pain post-treatment 
and up to 1-year after.5 A limitation to this study is that there was no randomization or control 
group. 
Day, ESWT for Shoulder Tendonitis    9 
CONCLUSION 
 
Based off of the studies analyzed, it has been determined that the evidence is inconclusive in 
determining if ESWT is effective in treating shoulder tendinitis, as the studies have opposing 
results. In the study conducted by Li et al, it was concluded that ESWT was safe and effective in 
treating non-calcified CRTC tendonitis. In the study conducted by Kvalvaag et al., it was 
concluded that ESWT provided no additional improvement in pain and level of disability in 
those with shoulder tendonitis (calcified and non-calcified). The improvement in both the 
interventional and control group may have been due to the supervised exercises, the common 
denominator in both groups. In the study conducted by Malliaropoulos et al., it was concluded 
that ESWT improved pain in those with calcified shoulder tendinopathy, and it was associated 
with a lower recurrence rate and higher remission rate up to 1-year post-treatment. 
Further studies are necessary to determine the type of shoulder tendinopathy that would 
most benefit from ESWT. The Kvalvaag et al. study did not separate their study population into 
calcified vs non-calcified RTC tendonitis. Although this made the study more generalizable, it 
skewed the results because the population was not specific. The study also included supervised 
exercises into the treatment protocol making it difficult to draw conclusions specifically about 
ESWT, since it was not an isolated intervention. Furthermore, there needs to be a larger study of 
design that is conducted for a longer duration of time, as shoulder tendonitis can take up to a year 
to heal post treatment.  
In the two studies that showed ESWT effective in treating RTC tendonitis, both studies 
included participants with chronic symptoms; Lei et al included those with pain lasting > 6 mo, 
and Malliaropoulos et al included those with a mean duration of pain of 12.5 months.6,5 
Therefore, future studies need to focus on a population that has CRTC tendonitis. Then, the study 
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can be further specified into calcified and noncalcified CRTC tendonitis. In conclusion, the 
studies on the effectiveness of ESWT in treating shoulder tendonitis were conflicting, and more 
specific studies need to be done before definitive conclusions can be made. 
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